Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Revenue (2022 - 2024)

Summit Therapeutics' Revenue history spans 2 years, with the latest figure at -$3.1 million for Q2 2024.

  • For Q2 2024, Revenue changed N/A year-over-year to -$3.1 million; the TTM value through Mar 2025 reached -$3.1 million, up 0.61%, while the annual FY2022 figure was $705000.0, 61.03% down from the prior year.
  • Revenue reached -$3.1 million in Q2 2024 per SMMT's latest filing, up from -$3.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $4.7 million in Q4 2022 to a low of -$3.1 million in Q1 2024.